Overview

A Study to Evaluate the Impact of Acid-reducing Agents on the Pharmacokinetics (PK) of AMG 510 in Healthy Participants

Status:
Completed
Trial end date:
2020-09-13
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the PK of AMG 510 alone and in combination with either famotidine or omeprazole in healthy participants under fed conditions.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Famotidine
Omeprazole